Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of “Hold” from Analysts

Esperion Therapeutics, Inc. (NASDAQ:ESPRGet Free Report) has been assigned a consensus recommendation of “Hold” from the five analysts that are covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $9.33.

A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, May 21st. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, May 7th. Finally, StockNews.com downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 17th.

Check Out Our Latest Research Report on ESPR

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Private Portfolio Partners LLC bought a new stake in Esperion Therapeutics during the fourth quarter worth approximately $30,000. Herbst Group LLC bought a new stake in Esperion Therapeutics during the first quarter worth approximately $28,000. CVI Holdings LLC bought a new stake in Esperion Therapeutics during the first quarter worth approximately $37,000. Simplicity Wealth LLC bought a new stake in Esperion Therapeutics during the first quarter worth approximately $44,000. Finally, PSI Advisors LLC raised its holdings in Esperion Therapeutics by 161.5% during the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 10,500 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Up 13.4 %

Shares of ESPR stock opened at $2.80 on Friday. The business has a 50 day moving average of $2.29 and a two-hundred day moving average of $2.27. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40. The company has a market cap of $530.49 million, a P/E ratio of -2.83 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPRGet Free Report) last issued its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.42. The company had revenue of $137.74 million during the quarter, compared to analyst estimates of $53.11 million. Analysts expect that Esperion Therapeutics will post -0.05 EPS for the current fiscal year.

About Esperion Therapeutics

(Get Free Report

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Further Reading

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.